Videos

Gary J. Schiller, MD, reviews recent data on durable transfusion independence for patients with lower-risk MDS in the IMerge phase 3 study and discusses how transfusion frequency affects patient outcomes.

An expert on myelodysplastic syndrome discusses the impact of mutational status on response in the IMerge phase 3 study.

Virginia Kaklamani, MD, DSc, details that disease burden and location of metastases in patients with HR+/HER2- metastatic breast cancer guide approaches to management, with visceral metastases indicating potentially faster progression and more concerning symptoms.

Virginia Kaklamani, MD, DSc, shares that in deciding second-line therapy for metastatic breast cancer after CDK4/6 inhibitors, endocrine sensitivity guides the choice between treatments based on ESR1/PIK3CA mutations and safety profiles with/without fulvestrant injections.

Bruno R. Bastos, MD, discusses findings from a study which assessed the pharmacodynamic and radiographic changes among patients with renal cell carcinoma who were treated with the combination of nivolumab and TPST-1120.

Martin H. Voss, MD, discusses what community oncologists should takeaway from the the extended follow-up data of the phase 2 KEYNOTE-B61 study which assessed first-line pembrolizumab plus lenvatinib for patients with non-clear cell renal carcinomas.

Chakra Chaulagain, MD, discusses the context of an analysis which assessed autologous hematopoietic stem cell transplantation refusal rates among patients with multiple myeloma.

Joseph M. Jacob, MD, discusses the key takeaways from the SunRISe-1 study and data presented at the 2024 Genitourinary Cancers Symposium.

Benjamin H. Lowentritt, MD, FACS, discusses findings from a United States real-world study of patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide.

Future perspective on the growing treatment landscape for patients with MDS.

Dr. Garcia-Manero provides an overview of the toxicity profiles for therapies and mitigation strategies for patients with lower-risk MDS.

Guillermo Garcia-Manero, MD, highlights data updates presented at ASH 2023, outlining current and emerging therapies in frontline and second line lower-risk myelodysplastic syndrome (MDS).

Thomas Powles, MD, MBBS, MRCP, discusses the mechanism of action of enfortumab vedotin-ejfv and its use in treating locally advanced or metastatic urothelial carcinoma.

Clinicians review the MEDALIST trial, which evaluated luspatercept in the second-line setting and comment on updated data from MEDALIST that was recently presented at the annual ASH 2023 meeting.

Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.

Matthew A. Powell, MD, discusses the methods and design of the randomized, double-blind, phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial in endometrial cancer.

Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.

Dr Shadman provides insightful discussion on optimizing outcomes with BTK inhibition in CLL through adverse event mitigation and sustaining treatment in later lines.

Expert perspective on evolving data and strategies for managing relapsed/refractory CLL.

Explore the primary treatment options for chronic Graft vs Host Disease (cGvHD) and delve into the challenges associated with prolonged steroid use, focusing on dosing strategies and adverse event management.

Federico Albrecht, MD, discusses the standard practice on testing for a patient with small cell lung cancer at Miami Cancer Institute.

Neeraj Agarwal, MD, highlights several exciting prostate cancer developments being presented at the upcoming 2024 Genitourinary Cancers Symposium.

Subgroup analyses from the EMERALD trial show that oral SERD elacestrant may outperform standard endocrine therapy in metastatic breast cancer patients with bone or visceral metastases who previously received CDK4/6 inhibitors.

Virginia Kaklamani, MD, DSc, explains that in second-line treatment of metastatic HR+/HER2- breast cancer after CDK4/6 inhibitors, biomarker testing guides the choice between therapies based on the safety and resistance mutation profiles.

Virginia Kaklamani, MD, DSc, reviews the presented case of a postmenopausal patient with breast cancer who develops metastases after adjuvant endocrine therapy ends, and explains that later treatment selection is difficult because of endocrine resistance and mutations causing more aggressive disease.

Practical insights for the management of patients with NDMM.

Summary of findings presented at the 2023 ASH meeting from this phase 2 trial using daratumumab, bortezomib, thalidomide and dexamethasone with tandem autologous stem cell transplant in high risk newly diagnosed multiple myeloma patients.

Review of the final analysis of data from the MASTER clinical trial assessing daratumumab plus carfilzomib, lenalidomide and dexamethasone.

Overview of findings from this phase 3 study evaluating isatuximab added to carfilzomib, lenalidomide and dexamethasone.

Review of the key primary outcome data from this trial of subcutaneous daratumumab with bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant eligible multiple myeloma patients.